Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Study Details
Study Description
Brief Summary
This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This study is an open, phase I study to evaluate the safety, tolerability, pharmacokinetics of DR30206 in patients with advanced or metastatic solid tumors. The study is composed of two parts: part A is Dose escalation stage and part B is Dose expansion stage
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: DR30206 Subjects receive DR30206 monotherapy intravenously(IV) until no more benefits from treatment. |
Drug: DR30206
Subjects receive DR30206 intravenously
|
Outcome Measures
Primary Outcome Measures
- PartA: Incidence of dose limiting toxicities (DLTs) [21 days following first dose]
Dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment
- PartA: Maximum tolerated dose (MTD) [21 days following first dose]
As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort
- PartA: Recommend dose of expansion(RDE) [21 days following first dose]
A Recommend dose of expansion will be determined based on safety data
- PartA+B: Adverse evens (AEs) [Up to 90 days after last dose]
The incidence and severity of AEs graded according to NCI-CTCAE v5.0
- PartA+B: Serious adverse evens (SAEs) [Up to 90 days after last dose]
A Serious Adverse Event (SAE) is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect
- PartB: Objective response rate (ORR) [Up to approximately 12 months]
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1
- PartB: Recommended phase 2 dose (RP2D) [21 days following first dose]
A recommended phase 2 dose will be determined based on safety data
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntarily sign a written informed consent form
-
Patients must be ≥ 18 and ≤75 years of age
-
Part A: Subjects with advanced or metastatic malignant solid tumors confirmed by histology or cytology who have failed or are intolerant to standard therapy or have no effective standard therapy
-
Part B: Subjects with advanced or metastatic specific types of tumors confirmed by histology or cytology who have failed or are intolerant to standard therapy or have no effective standard therapy
-
Patients in part A must have at least one evaluable lesion, and in part B must have at least one measurable lesion according to RECIST v1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0 or 1
-
The expected survival period ≥3 months
-
Adequate bone marrow, liver, and renal function
-
Male or female subjects with fertility must agree to take effective contraceptive measures during the study period and within 6 months after the end of the last medication
-
Be able to understand the procedures and methods of this study, and willing to strictly follow the clinical trial protocol to complete this study
Exclusion Criteria:
-
Patients with a history of severe allergies to monoclonal antibodies (mAb) or bispecific antibodies, or known allergies to drug component of the study drug
-
Patients with active malignant tumors within the past 2 years, except for the tumors participating in the study and locally cured tumors
-
Severe chronic or active infections, including but not limited to hospitalization due to complications of infection, bacteremia, or severe pneumonia, or any active infection that the investigator believes may affect the safety of the subject, within 4 weeks prior to the start of the study treatment; Systemic antibiotic treatment within 2 weeks before starting the study treatment
-
Received the following treatments or medications within 4 weeks before starting the study treatment: a. Interventional clinical studies; b. Major surgery or severe traumatic injury, or expected to require major surgery during the study process; c. Inoculate live attenuated vaccines, or expect to receive such vaccines during the study treatment period or within 5 months after the last administration of the study treatment; Systemic treatment with anti-tumor drugs, or local anti-tumor therapy, or treatment with systemic immune stimulators (including but not limited to interferon or interleukin-2 (IL-2)
-
Radical radiotherapy within 3 months before starting the study treatment
-
Received systemic immunosuppressive medication treatment within 4 weeks prior to the start of the study, or is expected to require systemic immunosuppressive medication during the study treatment period
-
Known active central nervous system (CNS) metastasis
-
There have been clinically significant cardiovascular and cerebrovascular diseases within 6 months prior to the first study drug dosing
-
Active stage of autoimmune disease or immune deficiency or history of autoimmune disease or immune deficiency
-
Have a history of interstitial pneumonia, idiopathic pulmonary fibrosis, organized pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia found on screening chest CT scans; Previously used hormone therapy for pneumonia
-
Active or previously diagnosed inflammatory bowel disease (such as Crohn's disease, ulcerative colitis)
-
During the screening period, there were a large or symptomatic moderate amount of pleural effusion, pericardial effusion, and abdominal effusion
-
During the screening period, imaging showed that the tumor were surrounded by important blood vessels or had obvious necrosis or cavities, and the investigators determined that enrolling into the study would pose a risk of bleeding
-
Previous or current complications such as gastrointestinal perforation surgery, wound healing, and bleeding events
-
Current or recent use of aspirin (>325 mg/day) or treatment with clopidogrel, clopidogrel, and cilostazol (within 10 days prior to the first study drug dosing)
-
Receiving full dose oral or parenteral anticoagulant or thrombolytic therapy, but still unstable for at least 2 weeks before the first study drug dosing
-
Adverse reactions caused by previous treatment that have not recovered to CTCAE 5.0 level 1 or below (but pigmentation, hair loss, etc. can be included if the investigator deems that there is no safety risk)
-
Known active infection
-
The subject has previously received allogeneic stem cell or organ transplantation
-
History of organ or hematopoietic stem cell transplantation that requires the use of immunosuppressants
-
Pregnant or lactating women, defined as women in a state of pregnancy until termination of pregnancy, are determined by laboratory human chorionic gonadotropin (hCG) testing within 7 days prior to the start of the study
-
Any other disease, medical condition or abnormality, metabolic dysfunction, alcohol or drug abuse or dependence, physical examination or lab testing results that potential impact on result interpretation or will increase the likelihood of complications for patients
-
Participants who are not appropriate for this clinical trial at the discretion of the investigator
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zhejiang Doer Biologics Co., Ltd.
Investigators
- Principal Investigator: Caicun Zhou, MD, Shanghai Pulmonary Hospital, Shanghai, China
- Study Chair: Yanshan Huang, PhD, Zhejiang Doer Biologics Co., Ltd.
- Study Director: Junfang Xu, MD, Huadong Medicine Co., Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DR30206101